1. How to Select Therapy in Relapsed/Refractory CLL

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Survival by Increased Lines of Chemotherapy

4. Factors Impacting Treatment Selection

5. Importance of FISH Testing

6. Considerations for Second-Line Chemotherapy

7. Results With Second-Line Chemotherapy

8. Second-Line Chemotherapy Combinations

9. Ibrutinib in Relapsed/Refractory CLL – RESONATE Trial

10. Idelalisib Clinical Trials

11. Idelalisib + Rituximab in Relapsed CLL

12. Venetoclax in del(17p) Relapsed CLL

13. Managing TLS

14. Venetoclax + Rituximab

15. Adverse Events With Ibrutinib

16. Chimeric Antigen Receptor T Cells

17. How Do You Choose?

18. Sequencing Novel Agents

19. Concluding Remarks